Cargando…

A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell–activating factor monoclonal antibody, for rheumatoid arthritis

INTRODUCTION: The objective of this study was to evaluate the long-term safety and efficacy of tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B-cell-activating factor, in rheumatoid arthritis (RA) patients. METHODS: Patients with RA who completed one of two 24-week rand...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenwald, Maria, Szczepanski, Leszek, Kennedy, Alastair, Veenhuizen, Melissa, Komocsar, Wendy J, Polasek, Emery, Guerrettaz, Kelly, Berclaz, Pierre-Yves, Lee, Chin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177512/ https://www.ncbi.nlm.nih.gov/pubmed/25168268 http://dx.doi.org/10.1186/s13075-014-0415-2

Ejemplares similares

Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study
por: Schiff, Michael, et al.
Publicado: (2015)

Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab
por: Hoffman, Robert W., et al.
Publicado: (2017)

Generation and characterization of tabalumab, a human monoclonal antibody that neutralizes both soluble and membrane-bound B-cell activating factor
por: Manetta, Joseph, et al.
Publicado: (2014)

Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2016)

Using Dermal Temperature to Identify Rheumatoid Arthritis Patients With Radiologic Progressive Disease in Less Than One Minute
por: Greenwald, Maria, et al.
Publicado: (2016)

52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study
por: Bae, Sang-Cheol, et al.
Publicado: (2022)

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients—REACTION 52-week study
por: Takeuchi, Tsutomu, et al.
Publicado: (2011)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study
por: Yataba, Ikuko, et al.
Publicado: (2016)

BAFF inhibition does not significantly impair immunization responses in patients with rheumatoid arthritis
por: Bingham, Clifton O., et al.
Publicado: (2015)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

An open-label, randomized controlled trial of sulfamethoxazole–trimethoprim for Pneumocystis prophylaxis: results of 52-week follow-up
por: Utsunomiya, Masako, et al.
Publicado: (2020)

Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study
por: Tanaka, Yoshiya, et al.
Publicado: (2014)

Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis
por: Nakajima, Arata, et al.
Publicado: (2019)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
por: Calabrese, Joseph R., et al.
Publicado: (2018)

Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study
por: Higuchi, Teruhiko, et al.
Publicado: (2021)

Guselkumab, a human interleukin‐23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52‐week, phase 3, multicenter, open‐label study
por: Sano, Shigetoshi, et al.
Publicado: (2018)

Immunocytochemical Labelling of Haematological Samples Using Monoclonal Antibodies
por: Erber, Wendy N.
Publicado: (2021)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Taurine supplementation for prevention of stroke-like episodes in MELAS: a multicentre, open-label, 52-week phase III trial
por: Ohsawa, Yutaka, et al.
Publicado: (2019)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

DNA methylation changes in infants between 6 and 52 weeks
por: Wikenius, Ellen, et al.
Publicado: (2019)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi‐center, open‐label, 52‐week phase 3 trial
por: Kuwabara, Satoshi, et al.
Publicado: (2018)

PM385. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies
por: Correll, Christoph U., et al.
Publicado: (2016)

Long-term safety and efficacy of rupatadine in Japanese patients with perennial allergic rhinitis: a 52-week open-label clinical trial
por: Okubo, Kimihiro, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Blonanserin Transdermal Patches in Japanese Patients with Schizophrenia: A 52-Week Open-Label, Multicenter Study
por: Iwata, Nakao, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 52-Week, Multicenter, Open-Label Extension Study
por: Saito, Takuya, et al.
Publicado: (2022)

Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study
por: Yamasaki, Kenshi, et al.
Publicado: (2022)

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
por: Paller, Amy S., et al.
Publicado: (2023)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Rituximab for Refractory Rheumatoid Arthritis: A 24-Week Open-Label Prospective Study
por: Ho, Ling Yin, et al.
Publicado: (2007)

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY(®) compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

A Year with Peter Drucker - 52 Weeks of Coaching for Leadership Effectiveness
por: Maciariello, Joseph
Publicado: (2014)

An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis
por: PUIG, Lluís, et al.
Publicado: (2020)

PS155. Long-term safety of adjunctive brexpiprazole (OPC-34712) in MDD: results from two 52-week open-label studies
por: Nelson, Craig, et al.
Publicado: (2016)

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c9d58a70g3jq68os1p17uu8obm